HAWTHORNE, N.Y.--Acorda Therapeutics, Inc. today announced that it has been selected for addition to the Nasdaq Biotechnology Index, which will be effective at the market's opening on Monday, November 20, 2006. "We are very pleased to be included in the NASDAQ Biotechnology Index and believe that our selection to this index is recognition of Acorda's consistent progress and achievements," said Ron Cohen, M.D., President and CEO of Acorda. "We are committed to delivering on our mission to develop therapies to restore neurological function to people with spinal cord injury, multiple sclerosis and other disorders of the nervous system."
The NASDAQ Biotechnology Index was launched in 1993 and includes contains securities of NASDAQ-listed companies that meet minimum requirements, including market value, average daily share volume, and seasoning as a public company, among other criteria. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Amex: IBB - News). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.
ACOR is trading up 65 cents or 4.4% at $15.27 in afternoon trading.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment